M
7.84
-0.19 (-2.37%)
| 前收盘价格 | 8.03 |
| 收盘价格 | 8.09 |
| 成交量 | 2,026,948 |
| 平均成交量 (3个月) | 1,931,964 |
| 市值 | 1,977,538,048 |
| 预期市盈率 (P/E Forward) | 370.37 |
| 价格/销量 (P/S) | 2.63 |
| 股市价格/股市净资产 (P/B) | 2.21 |
| 52周波幅 | |
| 利润日期 | 7 Nov 2024 |
| 营业毛利率 | -81.13% |
| 营业利益率 (TTM) | -23.09% |
| 稀释每股收益 (EPS TTM) | -1.67 |
| 季度收入增长率 (YOY) | -2.50% |
| 总债务/股东权益 (D/E MRQ) | 100.03% |
| 流动比率 (MRQ) | 10.74 |
| 营业现金流 (OCF TTM) | 29.89 M |
| 杠杆自由现金流 (LFCF TTM) | 8.86 M |
| 资产报酬率 (ROA TTM) | -1.61% |
| 股东权益报酬率 (ROE TTM) | -42.93% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Maravai LifeSciences Holdings, | 看跌 | 看涨 |
AIStockmoo 评分
-0.4
| 分析师共识 | -0.5 |
| 内部交易活动 | 0.0 |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.0 |
| 平均 | -0.40 |
|
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 1.45% |
| 机构持股比例 | 102.69% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 13.00 (RBC Capital, 65.82%) | 购买 |
| 中 | 9.00 (14.80%) | |
| 低 | 4.25 (Goldman Sachs, -45.79%) | 卖出 |
| 平均值 | 8.75 (11.61%) | |
| 总计 | 2 购买, 1 卖出 | |
| 平均价格@调整类型 | 5.08 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Goldman Sachs | 05 Dec 2024 | 4.25 (-45.79%) | 卖出 | 5.09 |
| 08 Oct 2024 | 7.00 (-10.71%) | 保留 | 7.68 | |
| Baird | 08 Nov 2024 | 9.00 (14.80%) | 购买 | 5.08 |
| RBC Capital | 08 Nov 2024 | 13.00 (65.82%) | 购买 | 5.08 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| ECKERT R ANDREW | 5.58 | - | 134,409 | 750,002 |
| LUCIER GREGORY T | 5.43 | 5.43 | 0 | 0 |
| 累积净数量 | 134,409 | |||
| 累积净值 ($) | 750,002 | |||
| 累积平均购买 ($) | 5.51 | |||
| 累积平均卖出 ($) | 5.43 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| ECKERT R ANDREW | 董事 | 16 Dec 2024 | 获得 (+) | 134,409 | 5.58 | 750,002 |
| LUCIER GREGORY T | 董事 | 09 Dec 2024 | 处理 (-) | 20,645 | 5.43 | 112,102 |
| LUCIER GREGORY T | 董事 | 09 Dec 2024 | 获得 (+) | 20,645 | 5.43 | 112,102 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合